I heard Gary was going to buy each of us one of these reports.<g> Take note of the following words... Microarray and Bioinformatics, both new markets for LDNA to penetrate.
(B*SNS WIRE) Insight and Information on the Genomic Revolution
Insight and Information on the Genomic Revolution
Business Editors and Health/Medical Writers
NEWTON UPPER FALLS, Mass.--(BUSINESS* WIRE)--Dec. 28, 1999--
Genomics will be one of the most powerful forces shaping the next
century, many experts are predicting. Approaches using proteomics,
single nucleotide polymorphisms (SNPs), functional genomics, biochips,
and functional genomics have caught lots of attention, but determining
exactly how this exciting new field will exert its influence is a
major challenge. "Genomic technologies hold the power to make drug
discovery and development faster and smarter," notes Phillips Kuhl,
President of Cambridge Healthtech Institute (CHI). "Right now, we are
seeing an explosion in the numbers of these technologies, and many
innovative ways of applying them."
Cambridge Healthtech Institute's new Genomic Reports provide a
comprehensive look at the players in this field and their
technologies, as well as valuable insights from its Editorial Advisory
Board members--comprised of leading experts from major pharmaceutical
companies, biotechnology concerns, and academia. No other source
provides as much detail on the current state of the field and the new
directions it is taking.
Each single report is approximately 80 pages long, and costs
$850. Even more cost-effective, a subscription of eight reports is
available for $5,000. This represents a cost saving of $1,800 compared
to buying the reports individually, providing subscribers with eight
reports for less than the price of six.
Topics included in the subscription series are: Proteomics,
Single Nucleotide Polymorphisms (SNPs), Functional Genomics, Biochips
and Microarrays, Target Validation, Gene Expression Analysis,
Bioinformatics, and The Top Genomics Technologies (based on CHI's
proprietary survey of leading experts in the field). The first two
reports Proteomics: A Key Enabling Tool for Genomics, and Single
Nucleotide Polymorphisms: Commercial and Scientific Prospects were
released in 1999. The rest of the topics will follow throughout 2000.
CHI will also be providing regular genomics news updates through
the company's new website, www.genomic-info.com, to be launched in
early 2000. The website will also feature access to information from
CHI's proprietary database of genomic deal information, which was
initiated in January 1999 and already contains information on over 300
genomics-related deals struck over the last year. "The combination of
these eight reports and the material on the website will guarantee
that our clients will be able to stay abreast of developments in all
the key aspects of genomics," says Malorye Branca, managing director
of CHI's publications series. "CHI's aim is to provide the highest
value information about genomics, in the most convenient way," Ms.
Branca adds. For more information please contact Vernette Roach at
tel: (617)630-1338, e-mail: vroach@healthtech.com, or visit
www.genomicreports.com.
--30--mp/bos*
CONTACT: Cambridge Healthtech Institute
Vernette Roach, (617)630-1338
vroach@healthtech.com
www.genomicreports.com
KEYWORD: MASSACHUSETTS
INDUSTRY KEYWORD: MEDICAL DEVICES
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: businesswire*.com
*** end of story ***
NEWTON UPPER FALLS, Mass.--(BW HealthWire*)--Dec. 28, 1999--Up until now,
most of the attention in genomics has been on sequencing, as researchers race
to complete
the map of the human genome and companies vie for the rights to genetic
sequence
information. ``We are entering the age of functional genomics now,' says Dr.
Allan B.
Haberman, leading author of Cambridge Healthtech Institute (CHI)'s new
report: Functional
Genomics: New Approaches For Higher Throughput and Greater Efficiency. ``And
this will determine more than anything, who
profits from the genomics revolution.'
Sequence information alone is not enough to lead to important new drug and
diagnostic discoveries. It is critical to understand
how genes work, how their protein products interact, and what roles they play
in health and disease. Many leading
pharmaceutical companies, including Merck, Novartis, and F. Hoffman-La Roche,
are making major investments in functional
genomics, often by partnering with smaller genomics and biotechnology
companies. Companies such as Cambridge Antibody
Technology, Exelixis, Lexicon, Millennium, Rigel, and Sangamo are offering
specialty services that should accelerate functional
genomics and improve the efficiency and effectiveness of drug target
identification and validation. Many experts believe that the
key to success for functional genomics companies is to offer an integrated
platform of services, and to provide large
pharmaceutical clients with ``validated' targets. Validated targets are
molecules that are proven to be critically involved in a
disease process; drugs that are specific for these targets are likely to have
therapeutic effects.
The CHI report covers the activities of leading companies and organizations
in the field, and provides profiles of over 15 of
these. Valuable insights about current trends and future directions are
provided by Editorial Advisory Board members,
including: Geoffrey Duyk, Exelixis; Giora Feurstein, Dupont Pharmaceuticals;
Glenn Freidrich, Lexicon Genetics; Carl Johnson,
Axys Pharmaceuticals; Paul J. Godowski, Genentech; Stephen Kingsmore,
Molecular Staging; Douglas Livingston, Novartis
Functional Genomics Institute; Jan Mous, F. Hoffmann-La Roche; Donald Payan,
Rigel, Inc.; Alan R. Williamson, Consultant;
and Kleanthis Xanthopolous, Aurora Biosciences.
The report will be available at the end of January. It is approximately 80
pages long and costs $850 for a single copy in print
format. Advance sales are currently being accepted. For more information
about this report, please contact Vernette Roach at
Tel: (617)630-1338, e-m |
